About Baymatob
Baymatob is an Australian healthcare AI company focused on transforming maternal and fetal health outcomes through its AI-guided maternity sensor, monitoring, and diagnostic platform called Oli. The company aims to address the significant challenges in maternal care, where current monitoring technologies are often decades old and fail to provide early warnings for critical complications. Oli is designed to empower healthcare providers by acquiring, interpreting, and predicting vital information about pregnancy progression and potential risks to both mothers and babies.
Specifically, Baymatob’s flagship product, Oli PPH, is being developed to identify individuals at a higher risk of developing postpartum hemorrhage (PPH) well before birth. PPH is a leading cause of preventable maternal death globally, and Oli PPH aims to provide essential advance warning, potentially an hour prior to blood loss, to allow for proactive clinical interventions and reduce the severity of outcomes such as emergency hysterectomy. The device is a wearable sensor that adheres to the mother’s abdomen, monitoring physiological signals including biopotentials, movement, temperature, and deformation. This technology has received FDA Breakthrough Device Designation, indicating its potential to significantly improve clinical practice. Beyond PPH, Baymatob envisions Oli as a comprehensive platform capable of providing insights into labor onset, time until birth, and early warnings for stillbirth, ultimately aiming to establish a new standard of care in maternal health.
Focus Areas
Business Intelligence
| Key Investors | Alberts Impact Ventures, Australian Unity's Future of Healthcare Fund, Global Bio Fund, Scale Investors, The University of Sydney, Pacific Channel, Brandon Biocatalyst, Edale Capital, ANDHealth |
| Partnerships | Woman's Hospital (USA), Royal North Shore Hospital (Australia), The Royal Hospital for Women (Australia) |
| Technology | AI-guided wearable sensor and diagnostics platform, cloud-connected digital platform |
| FDA Clearances | 1 (Breakthrough Device Designation for Oli) cleared products (estimated) |
What Physicians Need to Know
For physicians, Baymatob's Oli platform offers an unprecedented opportunity to move from reactive to proactive care in maternal health. The AI-guided sensor provides real-time, actionable insights and early warnings for critical complications like postpartum hemorrhage, potentially hours before traditional methods. This allows for crucial time to prepare and implement preventative measures, improving workflow efficiency and ultimately leading to safer outcomes for mothers and babies. The non-invasive and user-friendly design also supports women's choices in birth and integrates seamlessly into existing clinical workflows.
While specific integration partners are not detailed, the Oli platform is designed to be a digital platform that uses AI as an enhancement tool. Its ability to provide real-time data and insights suggests potential for integration with existing electronic health record (EHR) systems and other hospital monitoring platforms to streamline data flow and clinical decision-making. The company's focus on expanding equity of access also implies potential for integrations that support remote monitoring and community-based care.
What the Web Says
Baymatob is an Australian MedTech company focused on improving maternal and fetal health outcomes through its AI-guided labor monitoring device, Oli. The device aims to identify individuals at high risk of postpartum hemorrhage (PPH) before birth, a leading cause of preventable maternal death. The company has received FDA Breakthrough Device Designation for Oli and has completed a 500-patient pilot study in Australia, with a pivotal clinical trial commencing in the USA.
Overall: PositiveStrengths
- Oli device provides an early warning system for postpartum hemorrhage (PPH) at least an hour before birth, allowing for early intervention.
- The technology aims to transform and reinvent pregnancy and labor monitoring, which has seen little innovation.
- Oli is a wearable device, offering a more comfortable and less restrictive monitoring experience compared to traditional methods.
- The company is driven by a mission to reduce preventable maternal and fetal complications and deaths.
- Baymatob has a female-dominated, diverse, and passionate team.
- Oli has received FDA Breakthrough Device Designation, which streamlines the regulatory approval process.
Limitations
- No specific product or employer reviews were found on G2, Glassdoor, Capterra, or Reddit for Baymatob. The search results for these platforms yielded reviews for other companies with similar names or general healthcare IT solutions.
- The product, Oli, is still in clinical trials and not yet commercially available, so real-world user experiences are limited.
- One article mentions that pricing could be a limitation for low-budget companies regarding a clinical trial design software, which might be a general concern for advanced medical devices, but not specific to Baymatob.
Based on reviews from: Alberts, BioWorld, Baymatob (official website), PR Newswire, The University of Sydney
Last updated: 2026-06-20
Videos
News, demos, and interviews about Baymatob.
Videos load interactively. If none appear, search YouTube for Baymatob →
Press & Coverage
Frequently Asked Questions
Related Companies
QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]
Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]